Theravance Biopharma (NASDAQ:TBPH) Sees Unusually-High Trading Volume - Still a Buy?

Key Points

• Trading volume rose 39% to 769,058 shares, while Theravance Biopharma’s stock was essentially flat at $17.05. The shares remain below the analyst consensus target of $19.40.
• Analyst sentiment has weakened, with several firms downgrading the stock to “Hold” or “Neutral”; eight analysts now rate it Hold overall.
• The company missed quarterly expectations, reporting a $0.11 per-share loss versus a projected $0.07 profit and revenue of $20.73 million versus $22.49 million expected. Insiders sold about 350,000 shares worth $6.0 million over the past three months.

Theravance Biopharma, Inc. (NASDAQ:TBPH - Get Free Report) saw an uptick in trading volume on Tuesday . 769,058 shares traded hands during mid-day trading, an increase of 39% from the previous session's volume of 554,398 shares.The stock last traded at $17.0450 and had previously closed at $17.05.

Wall Street Analysts Forecast Growth

A number of equities analysts have weighed in on TBPH shares. Weiss Ratings upgraded shares of Theravance Biopharma from a "hold (c)" rating to a "hold (c+)" rating in a research report on Monday, August 17th. Zacks Research lowered shares of Theravance Biopharma from a "strong-buy" rating to a "hold" rating in a research report on Monday, September 7th. JonesTrading cut shares of Theravance Biopharma from a "buy" rating to a "hold" rating in a research note on Monday, June 29th. BTIG Research downgraded shares of Theravance Biopharma from a "buy" rating to a "neutral" rating in a research report on Monday, June 29th. Finally, HC Wainwright lowered shares of Theravance Biopharma from a "buy" rating to a "neutral" rating and raised their price target for the company from $15.00 to $17.00 in a research note on Tuesday, July 7th. Eight equities research analysts have rated the stock with a Hold rating, Based on data from MarketBeat.com, the stock has a consensus rating of "Hold" and a consensus target price of $19.40.

Theravance Biopharma Stock Up 0.1%

The company has a 50-day moving average of $16.96 and a 200 day moving average of $16.41. The stock has a market capitalization of $886.01 million, a PE ratio of 16.90 and a beta of 0.25.

Theravance Biopharma (NASDAQ:TBPH - Get Free Report) last announced its quarterly earnings data on Monday, August 10th. The biopharmaceutical company reported ($0.11) earnings per share for the quarter, missing analysts' consensus estimates of $0.07 by ($0.18). Theravance Biopharma had a net margin of 51.58% and a negative return on equity of 0.77%. The firm had revenue of $20.73 million during the quarter, compared to analysts' expectations of $22.49 million. As a group, equities analysts predict that Theravance Biopharma, Inc. will post 1.56 EPS for the current fiscal year.

Insider Activity

In other Theravance Biopharma news, major shareholder Eli Samaha sold 273,871 shares of the stock in a transaction dated Monday, June 29th. The shares were sold at an average price of $17.23, for a total value of $4,718,797.33. Following the completion of the sale, the insider owned 9,237,279 shares in the company, valued at approximately $159,158,317.17. This represents a 2.88% decrease in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, SVP Rhonda Farnum sold 13,314 shares of the stock in a transaction dated Tuesday, September 15th. The shares were sold at an average price of $17.03, for a total transaction of $226,737.42. Following the completion of the sale, the senior vice president owned 213,476 shares of the company's stock, valued at approximately $3,635,496.28. The trade was a 5.87% decrease in their position. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last three months, insiders sold 350,011 shares of company stock worth $6,016,830. Insiders own 7.65% of the company's stock.

Institutional Investors Weigh In On Theravance Biopharma

Hedge funds and other institutional investors have recently made changes to their positions in the stock. Squarepoint Ops LLC purchased a new stake in Theravance Biopharma in the 2nd quarter valued at $302,000. Groupe la Francaise purchased a new position in shares of Theravance Biopharma during the 2nd quarter worth $510,000. VIRGINIA RETIREMENT SYSTEMS ET Al purchased a new position in shares of Theravance Biopharma during the 2nd quarter worth $1,071,000. GTS Securities LLC purchased a new position in shares of Theravance Biopharma during the 2nd quarter worth $430,000. Finally, Hsbc Holdings PLC boosted its position in shares of Theravance Biopharma by 14.4% during the 2nd quarter. Hsbc Holdings PLC now owns 49,428 shares of the biopharmaceutical company's stock valued at $843,000 after acquiring an additional 6,224 shares during the last quarter. Institutional investors and hedge funds own 99.10% of the company's stock.

Theravance Biopharma Company Profile

Theravance Biopharma, Inc is a biopharmaceutical company focused on developing and commercializing medicines for serious respiratory and immune-mediated diseases. The company's work centers on therapies designed to address significant unmet medical needs and improve treatment options for patients.

Its principal commercial product is YUPELRI (revefenacin), a once-daily nebulized long-acting muscarinic antagonist used as a maintenance treatment for chronic obstructive pulmonary disease (COPD) in adults.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.